CBMG Breakthrough for Solid Tumor Treatment

Small Cap Nation Announces
Cellular Biomedicine Group (NASDAQ:CBMG)
Breakthrough for Solid Tumor Treatment

Marina del Rey - November 12, 2105 - Small Cap Nation reports that Cellular Biomedicine Group (NASDAQ:CBMG) has published positive results for its Cart-T cancer therapy clinical trial. Cart-T utilizes the body's own cells to fight off tumor growth and kill cancer cells. Accordingly, patients do not need to be subjected to chemo therapy with its negative side effects, often times killing cancer cells while at the same time also killing healthy body cells. 

Watch the Small Cap Nation Video Report on CBMG featuring comments from 
Dr. Yihong Yao, Chief Scientific Officer of CBMG 
and John McCamant, Editor and Publisher of


Continuing Improvement for CBMG
StockWatchIndex (SWI) initiated coverage of CBMG in February of 2015 at $16.50. While the stock is currently below its 52 week high, it has demonstrated consistent improvement over the last few weeks, we expect it to perform increasingly well moving forward and consider it a strong investment opportunity. The stock closed at $23.45 at the close of market yesterday.

About CBMG
Cellular Biomedicine Group Inc. (CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell-based technologies. CBMG is focused on developing and marketing safe and effective cell-based therapies based on its cellular platforms. CBMG is in an ongoing Phase IIa clinical trial evaluating the safety, feasibility and anti-tumor activity of its acquired Chimeric Antigen Receptor-Modified T-Cells (CAR-T) immunotherapy (CBM-CD20.1) targeting CD20 for the treatment of patients with advanced B-cell Non-Hodgkin lymphoma (NHL).

Please visit our research sites and
We would appreciate if you could pass our newsletter on to your friends and
colleagues, we always appreciate your feedback and comments.
About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site, its "Rise Above The Noise" newsletter and SWI Research site These services provide readers with information and research on new, often undiscovered and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. Our weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on for more detail.  SWI's  "Portfolio Performance Report" periodically reports about the performance of the stocks that we have purchased in our portfolio. typically hold and may be trading.  Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site  
Google +
Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp